49 year female known case of diabetes type 2 on metformin 1gm bd and glimiperide 2 mg bd her blood sugar fasting 118 and pp 180 came with complain of bilateral burning sensation of foot on and off increase since 2 weeks for that for that she was given methylcobalaine 1500 McG but the symptoms still persis on examination patient power 5/5 sensation intact planter down going how to manage this case
Reading File
Finding Sources
Finding Sources
Searching PubMed
diabetic peripheral neuropathy treatment
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
I now have enough information to give a thorough clinical answer. Let me synthesize everything.
Management of Painful Diabetic Peripheral Neuropathy (PDPN) - Case Analysis
Clinical Assessment First
This patient has painful diabetic peripheral neuropathy (PDPN) - specifically a distal symmetric polyneuropathy (DSPN). Key points from her examination:
- Power 5/5 - No motor involvement (typical of sensory-predominant DSPN)
- Sensation intact - Still in early-moderate neuropathy (loss of sensation is a later finding)
- Plantars downgoing - No upper motor neuron involvement (rules out myelopathy)
- Burning bilateral feet - Classic "stocking" distribution, worse recently = possibly related to glycemic variability
Her glycemic control is suboptimal - FBS 118 mg/dL (target <100) and PP 180 mg/dL (target <140 post-meal). This is an important modifiable factor.
The methylcobalamin 1500 mcg she received addresses B12 deficiency (an important co-factor, especially since metformin reduces intestinal B12 absorption). However, her symptoms persisting means neuropathic pain itself needs to be targeted.
Step 1 - Optimize Glycemic Control
This is foundational. The Diabetes Control and Complications Trial showed a 60% reduction in neuropathy risk with tight glycemic control (Tintinalli's Emergency Medicine).
Current regimen review:
- Metformin 1g BD - appropriate
- Glimepiride 2mg BD - note: twice-daily glimepiride is unusual (glimepiride is typically once daily due to its long half-life); confirm this is correct
Additions to consider:
- SGLT2 inhibitor (empagliflozin/dapagliflozin) - added cardiometabolic benefit, weight neutral, and helps glycemic control
- GLP-1 receptor agonist (semaglutide/liraglutide) - excellent postprandial glucose lowering, weight reduction (beneficial in T2DM neuropathy)
- Consider HbA1c testing to quantify overall control - target <7% ideally <6.5% in this age group
Step 2 - Pharmacological Treatment of Neuropathic Pain
Continue methylcobalamin - metformin does reduce B12 absorption. However, add specific neuropathic pain agents as below:
First-line agents (strong evidence):
| Drug | Dose | Notes |
|---|---|---|
| Duloxetine (SNRI) | 30 mg OD x 1 week, then 60 mg OD | FDA-approved for PDPN; also helps mood/sleep which commonly co-exist |
| Pregabalin | 75 mg BD, titrate to 150-300 mg/day | Strong evidence; helps sleep; adjust for renal function |
| Gabapentin | 300 mg OD at night initially, titrate up to 900-3600 mg/day | More side effects, less preferred but effective |
Second-line agents (moderate evidence):
- Amitriptyline 10-25 mg at bedtime - very cost-effective, effective for burning neuropathic pain; watch for anticholinergic effects and cardiac risk
- Venlafaxine 37.5-225 mg/day
- Sodium valproate 200-1200 mg/day (if other agents fail)
Topical agents (local, minimal systemic effects):
- Capsaicin cream (0.075%) applied to feet TID-QID - effective for burning; warn patient of initial worsening burning (TRPV1 desensitization)
- Lidocaine 5% patches - for localized pain (limited use on feet)
Best first choice for this patient: Start Duloxetine 30 mg OD for 1 week then increase to 60 mg OD - it addresses both neuropathic pain and any co-existing low mood/sleep disturbance, has strong evidence, and is generally well-tolerated in T2DM patients.
If duloxetine is not tolerated or contraindicated, use Pregabalin 75 mg BD (adjust if any renal impairment given her diabetes).
Step 3 - Continue and Optimize B12 Supplementation
Harrison's (2025) specifically notes: "Metformin may reduce intestinal absorption of vitamin B12 in type 2 DM... and may require sublingual or parenteral B12 replacement."
- Check serum B12 level if not already done
- If serum B12 is low-normal or deficient: switch to IM methylcobalamin 1000 mcg daily x 7 days, then weekly x 4 weeks, then monthly
- If serum B12 is normal, continue oral supplementation but reconsider contribution to symptoms
Step 4 - Alpha Lipoic Acid (ALA)
The SYDNEY 2 trial (referenced in Bradley & Daroff's Neurology) demonstrated that alpha-lipoic acid 600 mg TID orally improves sensory symptoms of diabetic polyneuropathy. This is an antioxidant that addresses the oxidative stress pathway in neuropathy pathogenesis.
- Alpha lipoic acid 600 mg OD or BD - can be added as adjunct; available OTC; particularly useful if patient prefers to avoid/minimize prescription medications
Step 5 - Non-Pharmacological Measures
- Foot care education - daily inspection of feet (especially important as sensation may worsen over time); use of protective footwear; avoid walking barefoot
- Exercise - regular moderate aerobic exercise improves nerve function and glycemic control
- Avoid neurotoxins - alcohol, smoking (both worsen neuropathy)
- Treat comorbidities - hypertension control is also important (BP target <130/80 in diabetics)
- Sleep hygiene - neuropathic pain is typically worse at night; addressing sleep often improves pain perception
Step 6 - Investigations to Order
| Test | Reason |
|---|---|
| HbA1c | Assess overall glycemic control over 3 months |
| Serum B12 | Confirm/rule out B12 deficiency (metformin effect) |
| Fasting lipids | Dyslipidemia worsens microvascular disease |
| Urine ACR/Creatinine | Check for diabetic nephropathy (affects drug dosing - pregabalin) |
| Renal function (eGFR) | Dose adjustment for pregabalin if needed |
| Thyroid function (TSH) | Hypothyroidism is a common reversible cause of neuropathy |
| NCS/EMG | If diagnosis unclear or atypical features (not mandatory here given classic picture) |
Summary Algorithm for This Patient
1. Optimize glycemia (HbA1c target <7%) → consider adding SGLT2i or GLP-1 agonist
2. Start Duloxetine 30mg OD → 60mg OD after 1 week
3. Check serum B12 → adjust methylcobalamin route if low
4. Add Alpha Lipoic Acid 600mg OD-BD
5. Foot care education + footwear + daily foot inspection
6. Investigate: HbA1c, B12, eGFR, lipids, TSH, urine ACR
7. Review in 4-6 weeks → if incomplete response, add Pregabalin 75mg BD
8. Refer pain management if refractory
Recent Evidence (2025): A Lancet Neurology systematic review and meta-analysis (Soliman et al., 2025 - PMID 40252663) on pharmacotherapy and non-invasive neuromodulation for neuropathic pain confirms that both gabapentinoids and SNRIs (duloxetine) remain the cornerstone of treatment for painful diabetic neuropathy.
Sources: Harrison's Principles of Internal Medicine 22E (2025), Tintinalli's Emergency Medicine, Bradley and Daroff's Neurology in Clinical Practice
Create a side-by-side comparison chart of PDN treatment options (duloxetine vs pregabalin vs gabapentin)
Generating Image
Here is the side-by-side comparison. Below is the full data in text form as well for quick reference:
PDN Treatment: Duloxetine vs Pregabalin vs Gabapentin
| Parameter | Duloxetine | Pregabalin | Gabapentin |
|---|---|---|---|
| Drug Class | SNRI | Alpha-2-delta ligand (gabapentinoid) | Alpha-2-delta ligand (gabapentinoid) |
| Mechanism | Inhibits serotonin + norepinephrine reuptake in descending pain pathways | Binds voltage-gated Ca²⁺ channels, reduces excitatory neurotransmitter release | Same as pregabalin (less predictable binding) |
| Starting Dose | 30 mg OD x 1 week | 75 mg BD | 300 mg OD at night |
| Target Dose | 60 mg OD (max 120 mg/day) | 150-300 mg/day in divided doses | 900-3600 mg/day in 3 divided doses |
| FDA Approved for PDN | ✅ Yes (2004) | ✅ Yes (2004) | ❌ No (off-label) |
| Time to Effect | 2-4 weeks | 1-2 weeks | 2-4 weeks |
| NNT (pain relief) | ~5 | ~4-5 | ~6-7 |
| Key Side Effects | Nausea, dry mouth, insomnia, increased BP, sexual dysfunction | Dizziness, somnolence, weight gain, peripheral edema | Dizziness, somnolence, ataxia, weight gain |
| Advantages | Also treats depression/anxiety (common comorbidities); no renal dose adjustment at standard doses; once daily dosing | Predictable absorption; helps sleep; quick onset; proven in RCTs | Widely available; very low cost; can titrate flexibly |
| Disadvantages | Avoid in uncontrolled hypertension; caution in hepatic disease; withdrawal syndrome if stopped abruptly | Requires renal dose adjustment; weight gain problematic in T2DM; Schedule V (abuse potential in some countries) | Highly variable bioavailability; TID dosing required; slower titration |
| Renal Adjustment | Not required (hepatically metabolized) | ✅ Required - reduce dose if eGFR <60 | ✅ Required - reduce dose if eGFR <60 |
| Hepatic Caution | ⚠️ Avoid if significant hepatic impairment | Minimal hepatic metabolism | Minimal hepatic metabolism |
| Weight Effect | Neutral to slight loss | Weight gain ++ | Weight gain + |
| Best For | First choice when depression/anxiety co-exists; patients on once-daily regimens; normal renal function | When rapid pain relief needed; sleep disturbance prominent; if SNRI not tolerated | When cost is a major concern; combination therapy add-on |
| Avoid When | MAOIs within 14 days; uncontrolled HTN; glaucoma | Renal failure (needs dose cut); heart failure with edema | Renal failure (significant dose reduction needed) |
Key Takeaway for your patient: Duloxetine is the preferred first-line choice given her profile (T2DM with likely mood impact from chronic pain, normal renal function implied, once-daily convenience). If response is partial after 4-6 weeks, adding low-dose pregabalin at night (combination therapy) is a well-supported strategy before escalating further.
Burning feet syndrome
Finding Sources
Finding Sources
Searching PubMed
burning feet syndrome etiology management
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is a comprehensive overview of Burning Feet Syndrome (BFS).
Burning Feet Syndrome (BFS)
Definition
Burning feet syndrome (also called Grierson-Gopalan syndrome) is a condition characterized by a hot, burning, painful sensation confined predominantly to the soles of the feet, often extending to the dorsum of the feet and lower legs. It is more a symptom complex than a single disease entity - it always warrants a search for an underlying cause.
Pathophysiology
BFS results from dysfunction of small nerve fibers (A-delta and C fibers) that carry pain and temperature signals. These are the thinnest, most metabolically vulnerable nerve fibers, making them:
- First affected by metabolic insults (diabetes, nutritional deficiency)
- First affected by toxic exposures
- Sensitive to ischemia and inflammatory processes
The burning quality specifically reflects spontaneous ectopic discharge from damaged small fibers - they fire without stimulus, creating the perception of heat/burning.
Causes - Differential Diagnosis
1. Metabolic / Endocrine
| Cause | Mechanism | Clues |
|---|---|---|
| Diabetes mellitus (most common) | Chronic hyperglycemia → oxidative stress → small fiber axonopathy | Known DM, poor glycemic control, stocking distribution |
| Hypothyroidism | Myxedematous infiltration of nerves | Weight gain, cold intolerance, constipation, delayed reflexes |
| Chronic kidney disease | Uremic toxin accumulation | Elevated creatinine, uremia features |
| Liver disease | Toxic metabolite accumulation | Jaundice, ascites |
2. Nutritional Deficiencies
| Deficiency | Notes |
|---|---|
| Vitamin B12 | Most common nutritional cause; especially with metformin use, veganism, pernicious anemia |
| Vitamin B1 (Thiamine) | Alcoholics, malabsorption; "wet beriberi" includes burning feet |
| Vitamin B5 (Pantothenic acid) | Rare; classic "burning feet" - small fiber neuropathy with dysesthesias (Goldman-Cecil Medicine) |
| Vitamin B3 (Niacin/B3 deficiency) | Presumed small-fiber neuropathy causing "burning feet"; treat with B-complex vitamins |
| Folate deficiency | Co-exists with B12 deficiency |
| Vitamin B6 toxicity (paradox) | Excess pyridoxine (>200 mg/day) can itself cause sensory neuropathy |
3. Small Fiber Neuropathy (Idiopathic / Cryptogenic)
- Affects predominantly elderly women
- Burning hands and feet without autonomic features
- Normal NCS (large fibers spared) - diagnosis requires skin punch biopsy showing reduced intraepidermal nerve fiber density (IENFD)
- Accounts for a significant proportion of "idiopathic" cases
- Associated with: Sjögren's syndrome, SLE, sarcoidosis, celiac disease
4. Toxic / Drug-Induced
| Agent | Notes |
|---|---|
| Alcohol | Direct neurotoxin + nutritional deficiency |
| Chemotherapy (cisplatin, vincristine, paclitaxel) | Toxic neuropathy |
| Isoniazid | B6-depleting neuropathy |
| Metronidazole, nitrofurantoin | Sensory neuropathy |
| Statins | Rare association |
| Heavy metals (arsenic, thallium) | Occupational exposure |
5. Structural / Entrapment
| Cause | Notes |
|---|---|
| Tarsal tunnel syndrome | Tibial nerve compression behind medial malleolus → burning sole of foot; positive Tinel's sign at tarsal tunnel |
| Morton's neuroma | Burning between 3rd-4th toes; worse with narrow footwear |
| Plantar fasciitis | More pain than burning; worse first step in morning |
6. Vascular
| Cause | Notes |
|---|---|
| Erythromelalgia | Episodic burning + redness + warmth of feet; relieved by cooling; associated with polycythemia vera, essential thrombocythemia |
| Peripheral arterial disease | Burning with claudication; absent pulses |
| Raynaud's phenomenon | Usually hands; can involve feet |
7. Systemic Inflammatory / Autoimmune
- Sjögren's syndrome (small fiber ganglionopathy/neuropathy)
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Sarcoidosis
- Vasculitis
8. Infectious
- HIV-associated distal sensory polyneuropathy
- Leprosy (pure neuritic - especially in endemic areas)
- Lyme disease
9. Hereditary
- Fabry disease (X-linked lysosomal storage disorder) - acral burning pain in young males
- Hereditary sensory and autonomic neuropathies (HSAN)
- Charcot-Marie-Tooth (some subtypes)
Clinical Features
- Burning, heat sensation predominantly in soles, extending to dorsum and lower leg
- Worse at night (classic)
- Relieved by cold surfaces / cold water (patients often sleep with feet outside blankets)
- May be accompanied by tingling, pins-and-needles, hyperesthesia (light touch feels painful)
- Normal motor exam in early/pure small fiber neuropathy (power and reflexes intact)
- Standard NCS may be normal (small fibers not tested by routine NCS)
Investigations
| Investigation | Purpose |
|---|---|
| FBS, HbA1c, OGTT | Diabetes / prediabetes |
| TSH, T3, T4 | Hypothyroidism |
| Serum B12, folate | Nutritional deficiency |
| Renal function (creatinine, eGFR) | CKD/uremic neuropathy |
| LFTs | Hepatic neuropathy |
| CBC | Anemia, polycythemia (erythromelalgia) |
| ANA, anti-SSA/SSB | Sjögren's, SLE |
| Serum protein electrophoresis (SPEP) | Paraproteinemic neuropathy |
| HIV serology | If risk factors |
| Leprosy slit-skin smear | Endemic areas |
| NCS/EMG | Large fiber assessment; normal in pure SFN |
| Skin punch biopsy (IENFD) | Gold standard for small fiber neuropathy diagnosis |
| Quantitative sensory testing (QST) | Warm/cold detection thresholds; detects SFN |
Management
Treat the Underlying Cause (Priority)
- Optimize glycemic control (diabetes)
- Thyroid hormone replacement (hypothyroidism)
- B12 injections (deficiency) - especially if on metformin
- B-complex vitamins (nutritional deficiency)
- Alcohol cessation
- Surgical decompression (tarsal tunnel syndrome)
- Aspirin + venesection (erythromelalgia/polycythemia)
Symptomatic Neuropathic Pain Relief
- Duloxetine 30-60 mg OD (first-line)
- Pregabalin 75-300 mg/day (first-line)
- Gabapentin 300-3600 mg/day (alternative)
- Amitriptyline 10-25 mg at night (cost-effective)
- Alpha lipoic acid 600 mg OD-BD (antioxidant; evidence in diabetic SFN)
- Capsaicin cream 0.075% applied to soles TID-QID (desensitizes TRPV1 channels)
- Lidocaine 5% patch (localized use)
Non-Pharmacological
- Sleep with feet uncovered or use cool water soaks before bed
- Avoid tight footwear; wear breathable socks
- Regular moderate exercise
- Avoid alcohol, smoking, neurotoxic drugs where possible
- TENS (transcutaneous electrical nerve stimulation) - moderate evidence
Key Distinguishing Point
In a patient presenting with burning feet, always ask:
- Both feet simultaneously? → Systemic (metabolic, toxic, nutritional)
- One foot or asymmetric? → Structural (tarsal tunnel, lumbar radiculopathy, mononeuropathy)
- Episodic with redness and warmth? → Erythromelalgia
- Better with cold? → Small fiber neuropathy, erythromelalgia
- Normal NCS? → Do skin biopsy to assess small fiber density
Sources: Harrison's Principles of Internal Medicine 22E (2025), Goldman-Cecil Medicine, Adams and Victor's Principles of Neurology 12th Ed, Bradley and Daroff's Neurology in Clinical Practice
This is a shared conversation. Sign in to Orris to start your own chat.